The Specialty Pharmacy Review Board™ — Examining Emerging Biologics for Difficult-to-treat or Severe Asthma
Jointly provided by
Impact Education, LLC    
This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

You Are Invited to a LIVE CME/CPE/CNE Webcast:
The Specialty Pharmacy Review Board™ — Examining Emerging Biologics for
Difficult-to-treat or Severe Asthma
Live Webcast

Live Webcast Dates

Tuesday December 4, 2018 12:30 PM - 2:00 PM ET
Wednesday January 23, 2019 1:00 PM - 2:30 PM ET

Click here to download the slides from this webcast.
  • New and emerging biologic therapies for difficult-to-treat or severe asthma
  • Techniques to assess asthma severity and symptom control
  • Cost implications of treating difficult-to-treat or severe asthma
  • Care management strategies to improve the coordination of care for patients with difficult-to-treat or severe asthma
Jeffrey Dunn, PharmD, MBA
Vice President, Clinical Strategy and Programs and Industry Relations
Magellan Rx Management
Edmund Pezalla, MD, MPH
Enlightenment Bioconsult, LLC
Steven G. Avey, MS, RPh, FAMCP
Vice President
Specialty Pharmacy Programs
MedImpact Healthcare Systems, Inc.
Michael Wechsler, MD
Professor of Medicine
Director, NJH Cohen Family Asthma Institute
Department of Medicine
National Jewish Health

  • Managed care pharmacy directors, clinical pharmacists, quality directors, medical directors
  • Pharmacy directors, specialty pharmacists, quality directors, care managers, registered nurses and other managed care and payer organization professionals

This program will feature a multidisciplinary faculty panel who will present best practices for implementing collaborative treatment and patient management decisions that lead to optimal outcomes for patients with severe asthma. This approach will enhance the audiences' ability to recommend and implement payer specific techniques to improve the continuity of care related to the impact of asthma management strategies on clinical outcomes, value, and economic consequences for the entire health care system. The Specialty Pharmacy Review Board™ — format will be similar to a mock pharmacy and therapeutics committee meeting, featuring an expert panel including a leading asthma specialist, a specialty pharmacy director, and managed care medical and pharmacy directors.


After completing the activity, participants should be better able to:
  • Discuss the current management of difficult-to-treat or severe asthma, including guideline recommendations and new and emerging treatments
  • Explore techniques to assess asthma severity and symptom control
  • Examine the implications for managed care of treating difficult-to-treat or severe asthma, including medical costs and resource utilization
  • Employ care planning strategies to increase the delivery of coordinated, multidisciplinary care for patients with difficult-to-treat or severe asthma
Opening Comments/Overview
Jeffrey Dunn, PharmD, MBA
Assessing the Clinical Benefits and Appropriate Use of Biologics for Difficult-to-treat or Severe Asthma
Michael Wechsler, MD
Integrating Emerging Biologic Therapies into Health Plan Asthma Treatment Algorithms
Edmund Pezalla, MD, MPH
Faculty Idea Exchange
Medical and Pharmacy Benefit Design Strategies for Biologic Therapies
Jeffrey Dunn, PharmD, MBA
Care Coordination Strategies to Enhance Patient Outcomes with Difficult-to-treat or Severe Asthma
Steven G. Avey, MS, RPh, FAMCP
Audience Question and Answer Session

Key Takeaways and Closing Comments
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008162-9999-18-403-L01-P
Type of Activity: Application

For Pharmacists: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to the CPE Monitor as required. After receipt of a completed activity evaluation form, you will be provided with instructions to have your credit immediately uploaded to the CPE Monitor.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

If you have any questions, please call (215) 619-8812 or email